Form 4: Arcturus Therapeutics Director Acquires Stock Options

Arcturus Therapeutics Holdings Inc. director Peter C. Farrell was granted stock options for 15,000 shares.

Summary

• Peter C. Farrell, a Director at Arcturus Therapeutics Holdings Inc., has been granted stock options.
• The options are for 15,000 shares of common stock.
• The transaction date was June 5, 2026, with an exercise price of $7.30 per share.
• These options vest monthly over a one-year period from the grant date.
• The options have an expiration date of June 5, 2036.
• This grant represents the annual award for Mr. Farrell's service as a Board member.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard director compensation and an alignment of interests, but does not provide new financial performance data.

Positives

• Director compensation through stock options aligns management interests with shareholders.
• The grant of options suggests continued confidence in the company's future prospects by a key insider.
• The vesting schedule over one year provides a retention incentive for the director.

Negatives

• The filing does not contain any negative information.

Risks

• The value of the stock options is subject to market fluctuations and the company's performance.
• If the company's stock price does not exceed the exercise price of $7.30, the options may not be exercised profitably.

Future Outlook

The grant of stock options with an exercise price of $7.30 and a future expiration date of June 5, 2036, implies a positive outlook for the company's stock performance, as the options are only valuable if the stock price increases.

Management Comments

• This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
• Shares underlying the option vest monthly over a one year period from the date of grant.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term shareholder value creation. This type of compensation is standard for board members in companies like Arcturus Therapeutics.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes directors to act in ways that benefit shareholders.
• Employees: While not directly impacting employees, such grants can be part of a broader compensation philosophy that may extend to other employee incentive programs.
• Management: The grant reinforces the director's role and commitment to the company's success.

Next Steps

• The stock options will vest monthly over a one-year period from the grant date.
• The director may exercise the options at any time after they vest, up to the expiration date of June 5, 2036, provided the stock price is above the exercise price.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Form 4, Stock Options, Director Compensation, Insider Transaction, Securities Exchange Act